CN104740403A - 一种治疗血虚阴亏型复发性口腔溃疡的药物及其制备方法 - Google Patents
一种治疗血虚阴亏型复发性口腔溃疡的药物及其制备方法 Download PDFInfo
- Publication number
- CN104740403A CN104740403A CN201510167973.9A CN201510167973A CN104740403A CN 104740403 A CN104740403 A CN 104740403A CN 201510167973 A CN201510167973 A CN 201510167973A CN 104740403 A CN104740403 A CN 104740403A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- fructus
- medicine
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000003814 drug Substances 0.000 title claims abstract description 74
- 230000000306 recurrent effect Effects 0.000 title claims abstract description 34
- 206010028034 Mouth ulceration Diseases 0.000 title claims abstract description 28
- 208000031971 Yin Deficiency Diseases 0.000 title claims abstract description 22
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 229940079593 drug Drugs 0.000 title claims description 22
- 239000008280 blood Substances 0.000 claims abstract description 85
- 210000004369 blood Anatomy 0.000 claims abstract description 82
- 230000007812 deficiency Effects 0.000 claims abstract description 47
- 210000000582 semen Anatomy 0.000 claims abstract description 45
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 25
- 235000000235 Euphoria longan Nutrition 0.000 claims abstract description 25
- 241000237364 Achatina fulica Species 0.000 claims abstract description 23
- 241000005787 Cistanche Species 0.000 claims abstract description 20
- 241001643642 Viticis Species 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 60
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 26
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 20
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 claims description 19
- 241001532036 Aspidistra Species 0.000 claims description 18
- 230000002829 reductive effect Effects 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 13
- 238000010438 heat treatment Methods 0.000 claims description 12
- 239000007921 spray Substances 0.000 claims description 12
- 238000000108 ultra-filtration Methods 0.000 claims description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 9
- 239000000284 extract Substances 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 239000008187 granular material Substances 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- 239000012535 impurity Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- 239000013521 mastic Substances 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 6
- 239000006228 supernatant Substances 0.000 claims description 6
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000012567 medical material Substances 0.000 claims description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 230000000274 adsorptive effect Effects 0.000 claims description 3
- 125000003158 alcohol group Chemical group 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 3
- 230000006837 decompression Effects 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 238000004090 dissolution Methods 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 238000004064 recycling Methods 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 230000001954 sterilising effect Effects 0.000 claims description 3
- 238000003809 water extraction Methods 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 abstract description 28
- 230000036407 pain Effects 0.000 abstract description 28
- 230000000694 effects Effects 0.000 abstract description 27
- 230000035876 healing Effects 0.000 abstract description 10
- 208000027418 Wounds and injury Diseases 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 230000008901 benefit Effects 0.000 abstract description 6
- 235000013372 meat Nutrition 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 230000004069 differentiation Effects 0.000 abstract description 4
- 235000013399 edible fruits Nutrition 0.000 abstract description 4
- 238000002626 targeted therapy Methods 0.000 abstract description 4
- 208000011580 syndromic disease Diseases 0.000 abstract description 3
- 241000237502 Ostreidae Species 0.000 abstract description 2
- 208000015181 infectious disease Diseases 0.000 abstract description 2
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 240000005528 Arctium lappa Species 0.000 abstract 1
- 235000003130 Arctium lappa Nutrition 0.000 abstract 1
- 235000008078 Arctium minus Nutrition 0.000 abstract 1
- 241001233914 Chelidonium majus Species 0.000 abstract 1
- 241000662330 Corydalis cheilanthifolia Species 0.000 abstract 1
- 206010052804 Drug tolerance Diseases 0.000 abstract 1
- 241000490229 Eucephalus Species 0.000 abstract 1
- 241001289529 Fallopia multiflora Species 0.000 abstract 1
- 235000001287 Guettarda speciosa Nutrition 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 241000334160 Isatis Species 0.000 abstract 1
- 240000000001 Ludisia discolor Species 0.000 abstract 1
- 240000007707 Mentha arvensis Species 0.000 abstract 1
- 235000018978 Mentha arvensis Nutrition 0.000 abstract 1
- 240000000249 Morus alba Species 0.000 abstract 1
- 235000008708 Morus alba Nutrition 0.000 abstract 1
- 241000392039 Oreas martiana Species 0.000 abstract 1
- 235000003283 Pachira macrocarpa Nutrition 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241001080798 Polygala tenuifolia Species 0.000 abstract 1
- 241000270708 Testudinidae Species 0.000 abstract 1
- 240000001085 Trapa natans Species 0.000 abstract 1
- 235000014364 Trapa natans Nutrition 0.000 abstract 1
- 241000218989 Trichosanthes Species 0.000 abstract 1
- 230000003467 diminishing effect Effects 0.000 abstract 1
- 239000006049 herbal material Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 235000020636 oyster Nutrition 0.000 abstract 1
- 230000000361 pesticidal effect Effects 0.000 abstract 1
- 235000009165 saligot Nutrition 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 32
- 208000025865 Ulcer Diseases 0.000 description 31
- 201000010099 disease Diseases 0.000 description 30
- 238000011282 treatment Methods 0.000 description 30
- 208000002399 aphthous stomatitis Diseases 0.000 description 29
- 231100000397 ulcer Toxicity 0.000 description 29
- 210000002216 heart Anatomy 0.000 description 28
- 210000000952 spleen Anatomy 0.000 description 27
- 235000009508 confectionery Nutrition 0.000 description 26
- 210000000214 mouth Anatomy 0.000 description 26
- 210000004072 lung Anatomy 0.000 description 25
- 210000003734 kidney Anatomy 0.000 description 22
- 210000004185 liver Anatomy 0.000 description 21
- 230000001717 pathogenic effect Effects 0.000 description 20
- 206010011224 Cough Diseases 0.000 description 19
- 206010037660 Pyrexia Diseases 0.000 description 17
- 210000002784 stomach Anatomy 0.000 description 14
- 239000003826 tablet Substances 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 13
- 206010010774 Constipation Diseases 0.000 description 12
- 210000003205 muscle Anatomy 0.000 description 11
- 206010030113 Oedema Diseases 0.000 description 9
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 9
- 206010022437 insomnia Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 230000035922 thirst Effects 0.000 description 9
- 206010062717 Increased upper airway secretion Diseases 0.000 description 8
- 210000000988 bone and bone Anatomy 0.000 description 8
- 208000026435 phlegm Diseases 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 8
- 238000002560 therapeutic procedure Methods 0.000 description 8
- 206010019233 Headaches Diseases 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000004438 eyesight Effects 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 241000411851 herbal medicine Species 0.000 description 7
- 210000000936 intestine Anatomy 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 210000000629 knee joint Anatomy 0.000 description 6
- 210000004877 mucosa Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 230000008506 pathogenesis Effects 0.000 description 6
- 231100000614 poison Toxicity 0.000 description 6
- 230000003014 reinforcing effect Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 206010068319 Oropharyngeal pain Diseases 0.000 description 5
- 206010033557 Palpitations Diseases 0.000 description 5
- 201000007100 Pharyngitis Diseases 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 206010003549 asthenia Diseases 0.000 description 5
- 210000001124 body fluid Anatomy 0.000 description 5
- 239000010839 body fluid Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 201000005884 exanthem Diseases 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 210000002200 mouth mucosa Anatomy 0.000 description 5
- 238000010791 quenching Methods 0.000 description 5
- 206010037844 rash Diseases 0.000 description 5
- 230000007958 sleep Effects 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- 230000008961 swelling Effects 0.000 description 5
- 210000003932 urinary bladder Anatomy 0.000 description 5
- 230000008673 vomiting Effects 0.000 description 5
- 208000006820 Arthralgia Diseases 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010059866 Drug resistance Diseases 0.000 description 4
- 206010013954 Dysphoria Diseases 0.000 description 4
- 208000010201 Exanthema Diseases 0.000 description 4
- 208000015220 Febrile disease Diseases 0.000 description 4
- 208000007117 Oral Ulcer Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 208000001431 Psychomotor Agitation Diseases 0.000 description 4
- 206010038743 Restlessness Diseases 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- LQGUBLBATBMXHT-UHFFFAOYSA-N chrysophanol Chemical compound C1=CC=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O LQGUBLBATBMXHT-UHFFFAOYSA-N 0.000 description 4
- 230000001276 controlling effect Effects 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 206010013781 dry mouth Diseases 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 208000013403 hyperactivity Diseases 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 201000001881 impotence Diseases 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 210000003800 pharynx Anatomy 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 231100000019 skin ulcer Toxicity 0.000 description 4
- 210000001584 soft palate Anatomy 0.000 description 4
- 210000002700 urine Anatomy 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 208000001387 Causalgia Diseases 0.000 description 3
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 3
- 206010010904 Convulsion Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010023126 Jaundice Diseases 0.000 description 3
- 206010062575 Muscle contracture Diseases 0.000 description 3
- 208000032023 Signs and Symptoms Diseases 0.000 description 3
- 208000009205 Tinnitus Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 208000005946 Xerostomia Diseases 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000014439 complex regional pain syndrome type 2 Diseases 0.000 description 3
- 208000006111 contracture Diseases 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 208000001780 epistaxis Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000003172 expectorant agent Substances 0.000 description 3
- 230000003419 expectorant effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 3
- 239000010931 gold Substances 0.000 description 3
- 229910052737 gold Inorganic materials 0.000 description 3
- 210000003026 hypopharynx Anatomy 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000003780 keratinization Effects 0.000 description 3
- 210000003127 knee Anatomy 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 239000002398 materia medica Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 230000001047 pyretic effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- -1 sublimed preparation Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000886 tinnitus Toxicity 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 244000241235 Citrullus lanatus Species 0.000 description 2
- 235000012828 Citrullus lanatus var citroides Nutrition 0.000 description 2
- 208000005171 Dysmenorrhea Diseases 0.000 description 2
- 206010013935 Dysmenorrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 206010061598 Immunodeficiency Diseases 0.000 description 2
- 208000029462 Immunodeficiency disease Diseases 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 206010027514 Metrorrhagia Diseases 0.000 description 2
- 208000005647 Mumps Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- 208000037048 Prodromal Symptoms Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 208000025747 Rheumatic disease Diseases 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001142 anti-diarrhea Effects 0.000 description 2
- 230000001754 anti-pyretic effect Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000002221 antipyretic Substances 0.000 description 2
- 230000001363 autoimmune Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 229940046011 buccal tablet Drugs 0.000 description 2
- 239000006189 buccal tablet Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 210000000589 cicatrix Anatomy 0.000 description 2
- 229940121657 clinical drug Drugs 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000916 dilatatory effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 208000017561 flaccidity Diseases 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 208000006750 hematuria Diseases 0.000 description 2
- 208000021760 high fever Diseases 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000007813 immunodeficiency Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000004089 microcirculation Effects 0.000 description 2
- 208000010805 mumps infectious disease Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 210000003254 palate Anatomy 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 2
- 230000000552 rheumatic effect Effects 0.000 description 2
- 238000009738 saturating Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 230000035900 sweating Effects 0.000 description 2
- 208000004371 toothache Diseases 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 210000001113 umbilicus Anatomy 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- GKAJCVFOJGXVIA-UHFFFAOYSA-N 4'-methoxy-3,3',5-stilbenetriol 3-glucoside Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(O)=CC(OC2C(C(O)C(O)C(CO)O2)O)=C1 GKAJCVFOJGXVIA-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 241000237360 Achatinidae Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002953 Aphonia Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000255791 Bombyx Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- VWDXGKUTGQJJHJ-UHFFFAOYSA-N Catenarin Natural products C1=C(O)C=C2C(=O)C3=C(O)C(C)=CC(O)=C3C(=O)C2=C1O VWDXGKUTGQJJHJ-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 241000207892 Convolvulus Species 0.000 description 1
- 241001522252 Crassostrea rivularis Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 241000195905 Dicranaceae Species 0.000 description 1
- OJIYIVCMRYCWSE-UHFFFAOYSA-M Domiphen bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CCOC1=CC=CC=C1 OJIYIVCMRYCWSE-UHFFFAOYSA-M 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 239000010282 Emodin Substances 0.000 description 1
- RBLJKYCRSCQLRP-UHFFFAOYSA-N Emodin-dianthron Natural products O=C1C2=CC(C)=CC(O)=C2C(=O)C2=C1CC(=O)C=C2O RBLJKYCRSCQLRP-UHFFFAOYSA-N 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- 241000371997 Eriocheir sinensis Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010015856 Extrasystoles Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- YOOXNSPYGCZLAX-UHFFFAOYSA-N Helminthosporin Natural products C1=CC(O)=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O YOOXNSPYGCZLAX-UHFFFAOYSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000015817 Infant Nutrition disease Diseases 0.000 description 1
- 206010061245 Internal injury Diseases 0.000 description 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241000158728 Meliaceae Species 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010059013 Nocturnal emission Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 241000308150 Orobanchaceae Species 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010033733 Papule Diseases 0.000 description 1
- 244000302909 Piper aduncum Species 0.000 description 1
- 235000016761 Piper aduncum Nutrition 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 241000219780 Pueraria Species 0.000 description 1
- 206010037294 Puerperal pyrexia Diseases 0.000 description 1
- 241000167686 Reichardia Species 0.000 description 1
- NTGIIKCGBNGQAR-UHFFFAOYSA-N Rheoemodin Natural products C1=C(O)C=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1O NTGIIKCGBNGQAR-UHFFFAOYSA-N 0.000 description 1
- 241000921453 Rhodobryum Species 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 206010041954 Starvation Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 206010053476 Traumatic haemorrhage Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 241000870995 Variola Species 0.000 description 1
- 241001073567 Verbenaceae Species 0.000 description 1
- 206010047601 Vitamin B1 deficiency Diseases 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 241000989077 Vitex rotundifolia Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000767 anti-ulcer Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 208000002894 beriberi Diseases 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- NZPQWZZXRKZCDU-UHFFFAOYSA-N chrysophanol Natural products Cc1cc(O)c2C(=O)c3c(O)cccc3Oc2c1 NZPQWZZXRKZCDU-UHFFFAOYSA-N 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- RHMXXJGYXNZAPX-UHFFFAOYSA-N emodin Chemical compound C1=C(O)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O RHMXXJGYXNZAPX-UHFFFAOYSA-N 0.000 description 1
- VASFLQKDXBAWEL-UHFFFAOYSA-N emodin Natural products OC1=C(OC2=C(C=CC(=C2C1=O)O)O)C1=CC=C(C=C1)O VASFLQKDXBAWEL-UHFFFAOYSA-N 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000002316 fumigant Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 230000002984 haematinic effect Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 210000001983 hard palate Anatomy 0.000 description 1
- 201000000615 hard palate cancer Diseases 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000012171 hot beverage Nutrition 0.000 description 1
- 230000009390 immune abnormality Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 208000021267 infertility disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- LWYXLXAMDLNBFQ-UHFFFAOYSA-N iso-6-Carnavalin Natural products CC(O)CCCCCCCCCCC1CCC(O)C(C)N1 LWYXLXAMDLNBFQ-UHFFFAOYSA-N 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229960001614 levamisole Drugs 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 230000001617 migratory effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 208000028284 monogenic inheritance Diseases 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- YKRGDOXKVOZESV-UHFFFAOYSA-N paeoniflorin Natural products O1C(C)(C2(CC34)OC5C(C(O)C(O)C(CO)O5)O)CC3(O)OC1C24COC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-UHFFFAOYSA-N 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000002640 perineum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- FFWOKTFYGVYKIR-UHFFFAOYSA-N physcion Chemical compound C1=C(C)C=C2C(=O)C3=CC(OC)=CC(O)=C3C(=O)C2=C1O FFWOKTFYGVYKIR-UHFFFAOYSA-N 0.000 description 1
- PKUBGLYEOAJPEG-UHFFFAOYSA-N physcion Natural products C1=C(C)C=C2C(=O)C3=CC(C)=CC(O)=C3C(=O)C2=C1O PKUBGLYEOAJPEG-UHFFFAOYSA-N 0.000 description 1
- OISYIJRGMYJBRH-UHFFFAOYSA-N physcione Natural products COc1cc(O)c2C(=O)c3ccc(O)cc3C(=O)c2c1 OISYIJRGMYJBRH-UHFFFAOYSA-N 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 230000010181 polygamy Effects 0.000 description 1
- 208000028280 polygenic inheritance Diseases 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- GKAJCVFOJGXVIA-QGLKVJOYSA-N rhaponticin Natural products COc1ccc(C=Cc2cc(O)cc(O[C@@H]3O[C@@H](CO)[C@@H](O)[C@H](O)[C@H]3O)c2)cc1O GKAJCVFOJGXVIA-QGLKVJOYSA-N 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 238000007665 sagging Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- GKAJCVFOJGXVIA-DXKBKAGUSA-N trans-rhaponticin Chemical compound C1=C(O)C(OC)=CC=C1\C=C\C1=CC(O)=CC(O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)=C1 GKAJCVFOJGXVIA-DXKBKAGUSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗血虚阴亏型复发性口腔溃疡的药物及其制备方法,其中,药物包括以下原料药材:当归、牡蛎肉、肉苁蓉、菟丝子、紫菀、血叶兰、褐云玛瑙螺、白芍、何首乌、楮实子、北沙参、麦冬、桑椹、龟甲、地柏枝、竹沥、知母、荸荠、栝楼、紫苏叶、川楝子、蔓荆子、大青叶、薄荷、牛蒡子、葛根、地骨皮、白薇、龙眼肉、山毛藓、刺五加、远志和柏子仁。本发明的有益效果是:本发明的药物,具有养血益阴,潜降虚火的功效,辨证论治靶向性治疗针对性强,消炎、止痛,愈合创面等,药效可直达病灶;不易产生耐药性、安全有效、毒副作用较小,提高治愈率,明显降低复发率;可明显提高患者的生活质量等;可进行临床市场推广的优势特点。
Description
技术领域
本发明涉及含有来源于植物、动物或矿物原料的医用配制品,特别涉及一种治疗血虚阴亏型复发性口腔溃疡的药物及其制备方法。
背景技术
复发性口腔溃疡又称为复发性阿弗他溃疡或复发性阿弗他口炎,是最常见的口腔粘膜病,其患病率居口腔粘膜病之首,各国流行病学调查显示每5人中至少有1人发生过口腔溃疡。该病以口腔黏膜各部位反复发作的溃疡为特征,不伴有其他疾病体征,具有周期性、复发性、自限性特征,溃疡灼痛明显。好发于唇、舌、颊、软腭等角化差的部位。
病理病因
病因复杂,存在明显的个体差异。研究报道的发病因素甚多,但尚无统一的确切说法,可能是多种因素的综合结果。
1.免疫因素
(1)细胞免疫异常:细胞免疫主要是指T淋巴细胞介导的免疫应答反应。细胞免疫主要由两类不同的T细胞亚类参与,一类是细胞毒T细胞(CTL),另一类是迟发型超敏T细胞(TDTH)。前者通过特异性的溶解破坏靶细胞,后者通过分泌淋巴因子引起非特异性效应细胞在特定部位集聚。因此,与细胞免疫有关的关键因素包括抗原、T细胞功能、淋巴因子以及机体的反应性。
(2)体液免疫异常和自身免疫:体液免疫是通过B淋巴细胞产生的特异性免疫球蛋白来实现的。自身免疫是抗体对来自自身的抗原的一种应答反应。
(3)免疫功能低下和免疫缺陷:有人证实RAU患者的淋巴细胞对PHA和刀豆蛋白(ConA)的反应在溃疡各个阶段都比正常人低下。用胸腺病毒作抗原刺激机体时,RAU患者的刺激反应亦属低下。HIV感染的RAU患者病情往往较重。说明RAU可能与免疫功能低下或免疫缺陷有关。
2.遗传因素
对RAU的单基因遗传、多基因遗传、遗传标记物和遗传物质的研究表明,RAU的发病有遗传倾向。
3.系统性疾病因素
临床实践经验和流行病学调查发现RAU与胃溃疡、十二指肠溃疡、溃疡性结肠炎、局限性肠炎有关联。
目前发病机制仍不明,有人提出复发性口腔溃疡的遗传、环境和免疫“三联因素论”,即遗传背景加上适当的环境因素(包括精神神经体质、心理行为状态、生活工作和社会环境等)引发异常的免疫反应而出现复发性口腔溃疡特征性病损。也有人提出“二联因素”论,即外源性因素(病毒和细菌)和内源性诱导因素(激素的变化、精神心理因素、营养缺乏、系统性疾病及免疫功能紊乱)相互作用而致病。目前复发性口腔溃疡的发生趋向于是多种因素综合作用的结果。
症状体征
本病分型颇多,可依形态大小、溃疡多少、溃疡深浅分型,尚无统一分型。从临床实用观点出发,将复发性口腔溃疡分3型,多采用世界公认的Lehner(1968)分型方法,即分为轻型、重型及疱疹样口炎。
1.轻型阿弗他溃疡最常见。约占RAU的80%。溃疡不大,一般直径2~4mm。圆或椭圆形,周界清晰,孤立散在,数目不多,每次发作1~5个。好发于角化程度较差的区域,如唇、颊黏膜。角化程度高的龈、腭部较少发生。发作时溃疡有“凹、红、黄、痛”特征。即溃疡中央凹陷,基底不硬,周边围有约1mm的充血红晕带,表面覆有浅黄色假膜,灼痛感明显。RAU复发有规律,一般分为发作期、愈合期和间歇期。发作期又细分为前驱期和溃疡期。前驱期有黏膜局部不适,触痛或灼痛感;约24h后出现白色或红色丘疹状小点;2~3天后上皮破损。进入溃疡期;再经4~5天后红晕消失,溃疡愈合,不留瘢痕。整个发作期一般持续1~2周,具有不治而愈的自限性。间歇期长短不一。因人而异。但一般初发间歇期较长,此后逐渐缩短。直至此起彼伏连绵不断。RAU因刺激痛影响语言、进食、心情,从而对生活质量产生不利影响。
2.疱疹样阿弗他溃疡又称阿弗他口炎。溃疡小而多,散在分布于黏膜任何部位,直径小于2mm,可达数十个之多,似有“满天星”感觉。邻近溃疡可融合成片,黏膜充血发红。唾液分泌增加,可伴头痛、低热、全身不适、局部淋巴结肿大等症状。
3.重型阿弗他溃疡。又称复发性坏死性黏膜腺周围炎、腺周口疮溃疡1~2个,大而深,直径可达1~3cm,深可达黏膜下层甚至达肌层,溃疡四周组织红肿,边缘略隆起,触诊较硬,溃疡有灰白色假膜覆盖,触痛明显,经1至数月愈合,愈后留有明显瘢痕。发生在软腭、软硬腭交界处、腭垂或软腭与咽旁处,可见瘢痕,色白,呈挛缩状,或腭垂缺损而变形。如发生在颊部口角处,因瘢痕挛缩,张口受限。重型口疮虽然溃疡大而深,愈合时间很长,自发痛、激发痛较剧烈,但一般无全身症状。
西医治疗复发性口腔溃疡主要目的是消炎、止痛,促进溃疡愈合,常用药物如:杜米芬含片,溶菌酶含片,西瓜霜,左旋咪唑等。但是,西医治疗复发性口腔溃疡所用药物毒副作用较大,易产生耐药性,目前尚无特效药物;疼痛明显者可应用烧灼、激光等治疗手段创伤性较大;复发率较高,给患者造成一定的精神压力,降低患者的生活质量。
中医学认为,复发性口腔溃疡属中医“口疮”、“口疡”范畴。“口疮”之名始见于《内经》。《素问·气交变大论》中曰:“岁金不及,炎火上行……民病口疮,甚则心痛。”首次指出口疮以火热为基本的发病因素。后世医家在此基础上,对其认识逐渐深入。如《丹溪心法·口齿》篇曰:“口疮服凉药不愈者,因中焦土虚,且不能食,相火冲上无制”,指出脾气虚弱与口疮有密切联系。《圣济总录》认为“口疮者,由心脾有热气冲上焦,熏发口舌,而为口疮。”指出了口疮与心脾二脏的关系。清·齐秉慧在《齐氏医案·口疮》中进一步提出“口疮上焦实热,中焦虚寒,下焦阴火,各经传变所致,当分辨阴阳虚实寒热而治之”,认为上焦实火熏蒸,下焦阴火上炎,中焦虚寒或脾虚湿困均为本病之病机。
中医分为以下几种类型:
1、外感时毒 口疮多发于外感后1~2天,伴有外感症状。初起口腔黏膜局部充血、红肿,微痛,舌尖或唇内出现栗粒样小红点或小疱疹,12小时内疱疹溃破,呈表浅溃疡,边界清楚。
2.心脾蕴热 症见口舌多处糜烂生疮,疮面红肿,灼热疼痛,甚则口臭牙龈肿痛,伴口渴多饮,尿黄便秘,舌红苔黄,脉滑数。
3.脾肾阳虚 症见口舌生疮,溃疡面色白,周围不红,数量少,久治不愈,伴四肢不温,口干喜热饮,腰背酸痛,尿频清长,大便溏,舌淡苔白腻,脉沉弱。
4.脾胃虚弱 症见口舌生疮反复发作,疮面色淡凹陷,伴神疲气短,不思饮食,四肢不温,大便稀溏,舌淡苔白,脉细弱。
5.虚火上炎 症见溃疡颜色鲜红,数量多,形状不一,大小不等,疼痛昼轻夜重,伴心悸心烦,失眠多梦,健忘,眩晕耳鸣,腰膝酸痛,咽干口燥,小便短黄,舌红苔薄,脉细数。
6.血虚阴亏 症见口舌溃烂多发生于月经前后,伴月经先期量多,五心烦热,口干喜饮,舌淡苔薄白,脉细数无力。
中医药治疗血虚阴亏型复发性口腔溃疡具有独特的优势,利用传统中医理论,在整体观念的基础上多靶点调节机体免疫力,改善微循环;辨证论治靶向性治疗针对性强,消炎、止痛,愈合创面等,药效可直达病灶;不易产生耐药性、安全有效、毒副作用较小,提高治愈率,明显降低复发率;可明显提高患者的生活质量等;可进行临床市场推广的优势特点。
发明内容
本发明所要解决的技术问题在于,提供了一种具有养血益阴,潜降虚火的功效,主治血虚阴亏型复发性口腔溃疡的药物。本发明具有利用传统中医理论,在整体观念的基础上多靶点调节机体免疫力,改善微循环;辨证论治靶向性治疗针对性强,消炎、止痛,愈合创面等,药效可直达病灶;不易产生耐药性、安全有效、毒副作用较小,提高治愈率,明显降低复发率;可明显提高患者的生活质量等;可进行临床市场推广的优势特点。
为了实现上述发明目的,本发明提供了一种具有治疗血虚阴亏型复发性口腔溃疡的药物,包括以下原料药材:当归、牡蛎肉、肉苁蓉、菟丝子、紫菀、血叶兰、褐云玛瑙螺、白芍、何首乌、楮实子、北沙参、麦冬、桑椹、龟甲、地柏枝、竹沥、知母、荸荠、栝楼、紫苏叶、川楝子、蔓荆子、大青叶、薄荷、牛蒡子、葛根、地骨皮、白薇、龙眼肉、山毛藓、刺五加、远志和柏子仁。
其中,所述药物中各原料药材的重量份数比可以优选为:当归12-23份、牡蛎肉10-18份、肉苁蓉20-30份、菟丝子8-16份、紫菀15-23份、血叶兰22-28份、褐云玛瑙螺10-21份、白芍15-26份、何首乌10-20份、楮实子12-23份、北沙参6-16份、麦冬13-27份、桑椹22-29份、龟甲8-15份、地柏枝16-25份、竹沥22-28份、知母10-23份、荸荠22-28份、栝楼8-14份、紫苏叶20-26份、川楝子5-9份、蔓荆子11-22份、大青叶22-32份、薄荷15-23份、牛蒡子17-24份、葛根10-24份、地骨皮16-28份、白薇11-25份、龙眼肉18-26份、山毛藓14-27份、刺五加10-19份、远志16-24份和柏子仁8-16份。
其中,所述药物中各原料药材的重量份数比还可以优选为:当归14-20份、牡蛎肉11-16份、肉苁蓉22-29份、菟丝子10-15份、紫菀17-21份、血叶兰23-27份、褐云玛瑙螺11-19份、白芍18-22份、何首乌13-18份、楮实子14-21份、北沙参8-15份、麦冬15-26份、桑椹23-27份、龟甲9-13份、地柏枝18-24份、竹沥24-27份、知母11-22份、荸荠23-26份、栝楼10-13份、紫苏叶21-25份、川楝子6-8份、蔓荆子12-21份、大青叶23-29份、薄荷16-21份、牛蒡子18-23份、葛根12-23份、地骨皮17-25份、白薇13-22份、龙眼肉19-25份、山毛藓15-25份、刺五加11-18份、远志17-23份和柏子仁10-15份。
其中,所述药物中各原料药材的重量份数比又可以优选为:当归14份、牡蛎肉15份、肉苁蓉29份、菟丝子15份、紫菀20份、血叶兰23份、褐云玛瑙螺16份、白芍22份、何首乌13份、楮实子21份、北沙参13份、麦冬15份、桑椹27份、龟甲11份、地柏枝24份、竹沥25份、知母11份、荸荠24份、栝楼13份、紫苏叶25份、川楝子6份、蔓荆子12份、大青叶25份、薄荷21份、牛蒡子18份、葛根23份、地骨皮17份、白薇22份、龙眼肉23份、山毛藓15份、刺五加18份、远志19份和柏子仁13份。
其中,所述药物中各原料药材的重量份数比还可以优选为:当归20份、牡蛎肉11份、肉苁蓉26份、菟丝子13份、紫菀17份、血叶兰27份、褐云玛瑙螺11份、白芍19份、何首乌15份、楮实子18份、北沙参15份、麦冬26份、桑椹23份、龟甲13份、地柏枝20份、竹沥24份、知母16份、荸荠23份、栝楼11份、紫苏叶21份、川楝子7份、蔓荆子15份、大青叶29份、薄荷18份、牛蒡子23份、葛根15份、地骨皮19份、白薇15份、龙眼肉19份、山毛藓25份、刺五加13份、远志17份和柏子仁15份。
其中,所述药物中各原料药材的重量份数比又可以优选为:当归16份、牡蛎肉16份、肉苁蓉22份、菟丝子10份、紫菀21份、血叶兰24份、褐云玛瑙螺19份、白芍18份、何首乌18份、楮实子14份、北沙参8份、麦冬20份、桑椹24份、龟甲9份、地柏枝18份、竹沥27份、知母22份、荸荠26份、栝楼10份、紫苏叶23份、川楝子8份、蔓荆子21份、大青叶23份、薄荷16份、牛蒡子19份、葛根23份、地骨皮25份、白薇13份、龙眼肉25份、山毛藓17份、刺五加11份、远志23份和柏子仁10份。
为解决上述技术问题,本发明还提供治疗血虚阴亏型复发性口腔溃疡的药物制备方法,其中当所述药物的剂型为含片剂时,其制备方法包括以下步骤:
第一步,将当归、菟丝子、褐云玛瑙螺、楮实子、地柏枝、竹沥、知母、葛根、地骨皮、刺五加和柏子仁按所述比例混合,用相对于获得的混合物质量的4~6倍的醇浓度90%~95%的乙醇浸泡,加热回流2~4小时后提取,过滤;将滤渣再次用相对于获得的混合物质量的2~4倍的醇浓度85%~95%的乙醇浸泡,加热回流1~2小时后提取,过滤;合并两次过滤液,减压回收乙醇并浓缩至药液浓度为0.8~1.2g生药/mL,利用体积为5L的大孔吸附树脂柱洗脱两次,先用5倍树脂柱体积的去离子水或蒸馏水洗脱,再用3倍树脂柱体积的醇浓度为90%~95%乙醇洗脱,收集乙醇洗脱液,减压浓缩除去乙醇,干燥并粉碎成粉末; 第二步,将牡蛎肉、白芍、何首乌、龟甲、荸荠、栝楼、白薇、龙眼肉、山毛藓和远志按所述比例混合,加相对于获得的混合物质量的3~5倍的醇浓度85%~95%的乙醇加热回流提取2次,两次提取液合并,用管式离心机离心除杂,将除杂后的提取液于60℃~70℃的条件下减压浓缩至60℃时相对密度为1.20~1.23的膏体,将浓缩后的膏体用喷雾干燥器干燥成粉末; 第三步,将剩余原料药材按所述比例混合,加相对于获得的混合物质量的2~5倍的水溶解,加热煎煮2~4小时,过滤;将滤渣再次用相对于获得的混合物质量的1~3倍的水浸泡,加热煎煮1~2小时,过滤;合并两次过滤液,减压浓缩除去水分,干燥并粉碎成粉末; 第四步,将第一步、第二步和第三步获得的粉末混合,进一步加入相对于获得的混合物质量0.05~0.1倍的羧甲基淀粉钠、0.05~0.1倍的微晶纤维素,混匀,制粒,干燥后,加入相对于获得的混合物质量0.01~0.05倍的硬脂酸镁,然后用冲压装置将颗粒压制成片,即得含片剂。
为解决上述技术问题,本发明还提供治疗血虚阴亏型复发性口腔溃疡的药物的制备方法,其中当所述药物的剂型为喷雾剂时,其制备方法包括以下步骤:
a、按所述比例称取所有原料药材,加相对于获得的混合物质量3-5倍的水浸泡3-10小时,武火煮沸后,改用文火慢煎30-50分钟至药液的剂量为100-300ml,煎煮3次,合并煎煮液过滤,滤液加热得浸膏1,药渣备用;
b、将步骤a的药渣加60-90%乙醇浸泡0.5-1.5小时,提取两次,每次1-2小时,合并提取液,80-160目滤过,取6000-10000转/分钟离心后的上清液,经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩得相对密度为80℃时1.35的浸膏2;
c、将浸膏1和浸膏2混合,加水稀释即得喷雾剂。
为解决上述技术问题,本发明还提供治疗治疗血虚阴亏型复发性口腔溃疡的药物的制备方法,其中当所述药物的剂型为滴剂时,其制备方法包括以下步骤:
a、取所述原料药加入水提取2次,第一次加4-6倍量水煎煮1-2小时,第二次加3-5倍量水煎煮1-2小时,将2次提取液合并,滤过,减压浓缩得80℃时相对密度为1.04~1.10的浸膏1,药渣备用;
b、将药渣加60-90%乙醇浸泡0.5-1.5小时,提取两次,每次1-2小时,合并提取液,滤过,浓缩,80-160目滤过,6000-10000转/分钟离心,取上清液,经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为60℃时1.25的浸膏2;
c、将浸膏1和浸膏2混合,加入混合浸膏总质量的0.06%的氯化钠和60-80倍的蒸馏水,并加入浓度为4%氢氧化钠溶液调节PH为6.0-7.0,再加入0.2%活性炭煮沸10分钟,滤过,分装,灭菌,即得滴剂。
为解决上述技术问题,本发明还提供一种治疗血虚阴亏型复发性口腔溃疡的药物,药物剂型为:片剂、薄膜衣片剂、肠溶衣片剂、糖衣片剂、胶囊剂、软胶囊剂、口服液、硬胶囊剂、冲剂、蜜丸剂、颗粒剂、散剂、丹剂、溶液剂、糖浆剂、乳膏剂、注射剂、擦剂、软膏剂、熏蒸剂、贴剂、栓剂、酊剂、硬膏剂和凝胶剂。
本发明实施例提供的技术方案带来的有益效果是:本发明的药物,具有养血益阴,潜降虚火的功效,主治血虚阴亏型复发性口腔溃疡,辨证论治靶向性治疗针对性强,消炎、止痛,愈合创面等,药效可直达病灶;不易产生耐药性、安全有效、毒副作用较小,提高治愈率,明显降低复发率;可明显提高患者的生活质量等;可进行临床市场推广的优势特点。
具体实施方式
祖国医学认为,复发性口腔溃疡多因外感燥火、饮食不节而生。如朱氏等根据“诸痛痒疮,皆属于心”及“舌为心之苗”的理论,认为复发性口腔溃疡主要系心火上炎所致。刘氏则认为多因过食辛辣醇酒以致心脾积热,循经上攻于口而发:或因素体阴虚,加之劳伤过度,亏耗真阴,虚火上炎而发。还有人认为是久病伤脾,水湿不运,郁而化热,湿热上蒸所致。总之,本病病机以“火”为主,与饮食劳倦、体质状况有关,与心脾两脏关系最为密切。
中医认为,治疗血虚阴亏型复发性口腔溃疡以养血益阴,潜降虚火为主要治疗原则,故选用方剂:当归、牡蛎肉、肉苁蓉、菟丝子、紫菀、 血叶兰、褐云玛瑙螺、白芍、何首乌、楮实子、北沙参、麦冬、桑椹、龟甲、地柏枝、竹沥、知母、荸荠、栝楼、紫苏叶、川楝子、蔓荆子、大青叶、薄荷、牛蒡子、葛根、地骨皮、白薇、龙眼肉、山毛藓、刺五加、远志和柏子仁。
方中当归、牡蛎肉、肉苁蓉、菟丝子、紫菀、 血叶兰、褐云玛瑙螺、白芍、何首乌、楮实子、北沙参、麦冬和桑椹养血滋阴健脾;龟甲、地柏枝、竹沥、知母、荸荠、栝楼、紫苏叶、川楝子、蔓荆子、大青叶、薄荷、牛蒡子、葛根、地骨皮和白薇滋阴潜阳、降火;龙眼肉、山毛藓、刺五加、远志和柏子仁养血安神。
其中,上述原料药材的药理如下:
当归:味甘、辛、苦,性温,入肝、心、脾经,《注解伤寒论》:“脉者血之府,诸血皆属心,凡通脉者必先补心益血,故张仲景治手足厥寒,脉细欲绝者,用当归之苦温以助心血。”《本草新编》:“当归,味甘辛,气温,可升可降,阳中之阴,无毒。虽有上下之分,而补血则一。入心、脾、肝三脏。但其性甚动,入之补气药中则补气,入之补血药中则补血,无定功也。”具有补血活血,调经止痛、润汤通便的作用,用于血虚萎黄、眩晕心悸、月经不调、经闭痛经、虚寒腹痛、肠燥便秘、风湿痹痛、跌扑损伤、痈疽疮疡等证。
牡蛎肉:为牡蛎科动物近江牡蛎、长牡蛎、大连湾牡蛎、密鳞牡蛎等的肉。 味甘;咸;性平。归心、肝经。养血安神;软坚消肿。主烦热失眠;悯神不安;瘰疬。
肉苁蓉:本品为列当科植物肉苁蓉的干燥带鳞叶的肉质茎。味甘、咸,性温。 归肾经、大肠经。补肾阳,益精血,润肠通便。用于阳痿,不孕,腰膝酸软,筋骨无力,肠燥便秘。①《本经》:主五劳七伤,补中,除茎中寒热痛,养五脏,强阴,益精气,妇人症瘕。②《别录》:除膀胱邪气,腰痛,止痢。③《药性论》:益髓,悦颜色,延年,治女人血崩,壮阳,大补益,主亦白下。④《日华子本草》:治男绝阳不兴,女绝阴不产,润五脏,长肌肉,暖腰膝,男子泄精,尿血,遗沥,带下阴痛。
菟丝子:本品为旋花科植物菟丝子的干燥成熟种子。味甘,温。归肝、肾、脾经。滋补肝肾,固精缩尿,安胎,明目,止泻。用于阳痿遗精,尿有余沥,遗尿尿频,腰膝酸软,目昏耳鸣,肾虚胎漏,胎动不安,脾肾虚泻;外治白癜风。
紫菀:味辛,苦,温。入心、肺二经。温肺,下气,消痰,止咳。治风寒咳嗽气喘,虚劳咳吐脓血,喉痹,小便不利。
血叶兰: 味甘;性凉。 滋阴润肺;健脾;安神。主肺痨咯血;食欲不振;神经衰弱。
褐云玛瑙螺:为玛瑙螺科动物褐云玛瑙螺的肉。味甘;性平。滋阴养血。主高血压;冠心病。
白芍:味苦、酸,性微寒,入肝、脾经,有养血合营,柔肝止痛,平抑肝阳的作用,主要用于肝阴不足、肝阳上亢之头痛脑胀、眩晕耳鸣、烦躁易怒;肝血不足,营卫空虚之月经不调,崩中漏下;肝虚血滞湿阻之痛经;营卫不和,营阴外越之自汗盗汗;肝气郁结之脘腹胁肋疼痛,泻痢腹痛;肝阴亏虚,经脉失养之手足痉挛疼痛等证,芍药甙有抗菌、解热、抗炎、增加冠状动脉流量、改善心肌营养血流、扩张血管、对抗急性心肌缺血、抑制血小板聚集、镇静、镇痛、解痉、抗溃疡、调节血糖的作用。有抗血栓形成及保肝作用,对痢疾杆菌、伤寒杆菌、血溶性链球菌、肺炎双球菌、绿脓杆菌、金黄色葡萄球菌有抑制作用。
何首乌:味甘、微苦,性平;归心、肝经,具有能养心安神、祛风通络的功效,主治失眠多梦,血虚身痛,风湿痹痛;皮肤瘙痒等证,首乌藤能够活血、通经、扩张血管、促进血液循环、下乳消肿。具有促进造血功能,增强免疫功能,降血脂与抗动脉粥样硬化,保肝,何首乌含有大黄酚、大黄素、大黄酸、大黄素甲醚、脂肪油、淀粉、糖类、土大黄甙、卵磷脂等有效成分。药理研究证明,何首乌能促进人体淋巴母细胞的转化。尚有降低血清胆固醇、抗动脉硬化、抗光毒等作用。
楮实子:甘,寒。入肝,脾、肾经。《日华子本草》:“壮筋骨,助阳气,补虚劳,助腰膝,益颜色。”《大名本草》:“壮筋骨、助阳气、补虚劳、助腰膝、益颜色。”补肾清肝,明目,利尿。用于腰膝酸软、虚劳骨蒸、砂晕目昏、目生翳膜、水肿胀满。楮实,书言味甘气寒,虽于诸脏阴血有补。得此颜色润,筋骨壮,腰膝健,肌肉充,水肿消,以致阴痿起,阳气助,是明指其阳旺阴弱,得此阴血有补,故能使阳不胜而助,非云阳痿由于阳衰,得此可以助阳也。若以纯阴之品可以补阳,则于理甚不合矣。
北沙参:性微寒,味甘、微苦。养阴清肺,益胃生津。用于肺热燥咳、劳嗽痰血、热病津伤口渴。北沙参含有挥发油、香豆素、淀粉、生物碱、三萜酸、豆甾醇、各甾醇,沙参素等成分。实验证明,北沙参能提高T 细胞比值,提高淋巴细胞转化率,升高白细胞,增强巨噬细胞功能,延长抗体存在时间,提高B 细胞,促进免疫功能。北沙参可增强正气,减少疾病,预防癌症的产生。
麦冬:性甘、微苦,微寒;归心、肺、胃经。具有养阴生津,润肺清心的功效,可用于喉痹咽痛,津伤口渴,内热消渴,心烦失眠,肠燥便秘等。清养肺胃之阴多去心用,滋阴清心多连心用。该品甘寒清润,善治胃阴不足,舌干口渴,纳呆不饥等证。此外,还可用治阴虚肠燥,大便秘结者。
桑椹:甘、平,无毒。补虚益气,去水气。桑叶降血压,清肝明目。嫩桑枝去风湿,治臂痛。桑根白皮利尿、止咳、治浮肿。桑椹中的脂肪酸具有分解脂肪、降低血脂,防止血管硬化等作用。桑椹含有乌发素,能使头发变的黑而亮泽。桑椹有改善皮肤血液供应,营养肌肤,使皮肤白嫩及乌发等作用,并能延缓衰老。桑椹具有免疫促进作用,可以防癌抗癌。桑椹善滋阴养血、生津润燥,适于肝肾阴血不足及津亏消渴,肠燥等症。常食桑椹可以明目,缓解眼睛疲劳干涩的症状。
龟甲:咸、甘,微寒;归肝、肾、心经。《本草纲目》:“补心、补肾、补血,皆以养阴也……观龟甲所主诸病,皆属阴虚血弱。”滋阴潜阳,益肾强骨,养血补心。用于阴虚潮热,骨蒸盗汗,头晕目眩,虚风内动,筋骨痿软,心虚健忘。
地柏枝: 甘;辛;平。归肝、胆、肺经。 清热利湿,滋阴降火;止血。主肺热咯血;吐血;衄血;便血;痔疮出血;外伤出血;发热;小儿惊风;湿热黄疸;淋病;水肿;水火烫伤。
竹沥: 甘,凉。入心、肝、肺三经。 清热豁痰。用于中风痰壅,肺热喘咳,热病烦躁。《本草再新》:清心火,降肝火,化痰止渴,解热除烦,治牙痛,明眼目。
栝楼: 为葫芦科植物栝楼的果实。甘苦,寒。归肺、胃、大肠经。清热化痰;宽胞散结;润燥滑肠。主肺热咳嗽;胸痹;消渴;便秘;痈肿疮毒。
知母:味苦、甘,性寒;归肺、胃、肾经,有泻热除烦,滋阴润燥、清肺止咳的作用,主治外感热病,高热烦躁,肺热燥咳,内热消渴等症状;其苦寒质润,性沉降,既能清热,又能生津,善治温热病邪入气分,热盛伤津;也用于治疗消渴症;痰热壅肺而喘,肺燥咳嗽,痰少不利;阴虚火旺,虚火上炎等症状。
荸荠:味甘;性寒。归肺、胃经。 清热,化痰,消积。治愠病消渴,黄疸,热淋,痞积,目赤,嚼喉肿痛,赘疣。
紫苏叶:辛,温。 归肺、脾经。 解表散寒,行气和胃。用于风寒感冒,咳嗽呕恶,妊娠呕吐,鱼蟹中毒。
川楝子:本品为楝科植物川楝的干燥成熟果实。 苦,寒。归肝、小肠、膀胱经。除湿热,清肝火,止痛,杀虫。治热厥心痛,胁痛,疝痛,虫积腹痛。《医林纂要》:泻心火,坚肾水,清肺金,清肝火。
蔓荆子:本品为马鞭草科植物单叶蔓荆或蔓荆的干燥成熟果实。辛、苦,微寒。归膀胱、肝、胃经。 疏散风热,清利头目。治风热感冒,正、偏头痛,齿痛,赤眼,目睛内痛,昏暗多泪,湿痹拘挛。
大青叶:苦,寒。归心、胃经。 清热解毒,凉血消斑。用于温邪入营,高热神昏,发斑发疹,黄疸,热痢,痄腮,喉痹,丹毒,痈肿。
薄荷:性味辛,凉。入肺经、肝经。用于风热感冒,温病初起。该品辛以发散,凉以清热,清轻凉散,为疏散风热常用之品,故可用治风热感冒或温病初起,邪在卫分,头痛、发热、微恶风寒者,常配银花、连翘、牛蒡子、荆芥等同用。用于头痛目赤,咽喉肿痛。该品轻扬升浮、芳香通窍,功善疏散上焦风热,清头目、利咽喉。用治风热上攻,头痛目赤,多配合桑叶、菊花、蔓荆子等同用;用治风热壅盛,咽喉肿痛 ,常配桔梗、生甘草、僵蚕、荆芥、防风等同用。
牛蒡子:味辛、苦、性寒。归肺、胃经。可疏散风热、清热解毒透疹、宣肺利咽散肿。主治风热感冒、温病初起;风热或肺热咳嗽、咯痰不畅;咽喉肿痛;斑疹不透;麻疹初期,疹出不畅及风疹瘙痒;疮疡肿毒及痄腮等。生用可润肠通便,热毒咽喉红肿疼痛,兼有热结便秘尤宜。《本草经疏》曰:“恶实,为散风除热解毒之要药。辛能散结,苦能泄热,热结散则脏气清明,故明目而补中。风之所伤,卫气必壅,壅则发热,辛凉解散则表气和,风无所留矣。藏器主风毒肿诸痿;元素主润肺、散结气、利咽膈、去皮肤风、通十二经络者,悉此意耳。故用以治瘾疹、痘疮,尤获奇验”。
葛根:性凉,味甘、辛,入脾、胃经。明朝著名的医学家李时珍对葛根进行了系统的研究,认为葛根的茎、叶、花、果、根均可入药。他在《本草纲目》中这样记载:“葛,性甘、辛、平、无毒,主治:消渴、身大热、呕吐、诸弊,起阴气,解诸毒”。可升阳解肌,透疹止泻,除烦止温。治伤寒、温热头痛项强,烦热消渴,泄泻,痢疾,癍疹不透,高血压,心绞痛,耳聋。
地骨皮:性寒,味甘;入肺、肝、肾经。《别录》:"主风湿,下胸胁气,客热头痛,补内伤大劳嘘吸,坚筋,强阴,利大小肠,耐寒暑。"《本草述》:"主治虚劳发热,往来寒热,诸见血证、鼻衄、咳嗽血,咳嗽、喘,消瘅,中风,眩晕,痉痼,腰痛,行痹,脚气,水肿,虚烦,悸,健忘,小便不通,赤白浊。"凉血除蒸,清肺降火。主治阴虚劳热,骨蒸盗汗,小儿疳积发热,消渴,肺咳喘,吐血,衄血,尿血。
白薇:《现代实用中药》:治卒中患者之四肢浮肿,又用于急性热病中末期之灼热及衰弱病之消耗热,肺结核之骨蒸潮热等,有清凉性滋养之效;又用于小溲亦涩,肺热咳嗽等证。清热凉血,利尿通淋,解毒疗疮。用于温邪伤营发热,阴虚发热,骨蒸劳热,产后血虚发热,热淋,血淋,痈疽肿毒。
龙眼肉:《滇南本草》:“养血安神,长智敛汗,开胃益脾。”《泉州本草》:“壮阳益气,补脾胃。治妇人产后浮肿,气虚水肿,脾虚泄泻。补益心脾,”养血安神。用于气血不足、心悸怔忡、健忘失眠、血虚萎黄。龙眼所含糖分量很高,为易消化吸收的单糖,可以被人体直接吸收,故体弱贫血,年老体衰,久病体虚,经常吃些龙眼是很有补益作用;妇女产后,龙眼也是重要的调补食品。因含铁及维生素B2很丰富,可以减轻子宫收缩及宫体下垂感。
山毛藓:苔藓类曲尾藓科山毛藓属植物山毛藓,以全草入药。 甘、淡,平。 养阴清热,养血安神。用于阴虚潮热,神经衰弱,癫狂,筋骨疼痛。
刺五加: 辛、微苦,温。 归脾、肾、心经。 益气健脾,补肾安神。用于脾肾阳虚,体虚乏力,食欲不振,腰膝酸痛,失眠多梦。
远志:苦、辛,微温;归心、肾、肺经。《神农本草经》:“主咳逆伤中,补不足,除邪气,利九窍,益智慧,耳目聪明,不忘,强志倍力。”《日华子本草》:“主膈气惊魇,长肌肉,助筋骨,妇人血噤失音,小儿客忤。”安神益智,祛痰,消肿失眠多梦,健忘惊悸,神志恍惚。失眠多梦,心悸怔忡,健忘。癫痫惊狂,痉挛抽搐,痈疽疮毒。
柏子仁:甘,平。归心、肾、大肠经。《神农本草经》:“柏实,味甘平,主惊悸,安五脏,益气,除风湿痹,久服令人润泽,美色,耳目聪明。”《本草纲目》:“养心气,润肾燥,安魂定魄,益智宁神。”“柏子仁性平而不寒不燥,味甘而补,辛而能润,其气清香,能透心肾,益脾胃。”养心安神,润肠通便。用于虚烦不眠,心悸怔忡,肠燥便秘等症。
以下采用实施例来详细说明本发明的实施方式,借此对本发明如何应用技术手段来解决技术问题,并达成技术效果的实现过程能充分理解并据以实施。
实施例1 本发明的含片剂
取当归14g、牡蛎肉15g、肉苁蓉29g、菟丝子15g、紫菀20g、血叶兰23g、褐云玛瑙螺16g、白芍22g、何首乌13g、楮实子21g、北沙参13g、麦冬15g、桑椹27g、龟甲11g、地柏枝24g、竹沥25g、知母11g、荸荠24g、栝楼13g、紫苏叶25g、川楝子6g、蔓荆子12g、大青叶25g、薄荷21g、牛蒡子18g、葛根23g、地骨皮17g、白薇22g、龙眼肉23g、山毛藓15g、刺五加18g、远志19g和柏子仁13g。
其制备方法包括以下步骤:
第一步,将当归、菟丝子、褐云玛瑙螺、楮实子、地柏枝、竹沥、知母、葛根、地骨皮、刺五加和柏子仁按所述比例混合,用相对于获得的混合物质量的4倍的醇浓度95%的乙醇浸泡,加热回流2小时后提取,过滤;将滤渣再次用相对于获得的混合物质量的4倍的醇浓度95%的乙醇浸泡,加热回流1小时后提取,过滤;合并两次过滤液,减压回收乙醇并浓缩至药液浓度为0.8g生药/mL,利用体积为5L的大孔吸附树脂柱洗脱两次,先用5倍树脂柱体积的去离子水或蒸馏水洗脱,再用3倍树脂柱体积的醇浓度为95%乙醇洗脱,收集乙醇洗脱液,减压浓缩除去乙醇,干燥并粉碎成粉末; 第二步,将牡蛎肉、白芍、何首乌、龟甲、荸荠、栝楼、白薇、龙眼肉、山毛藓和远志按所述比例混合,加相对于获得的混合物质量的4倍的醇浓度95%的乙醇加热回流提取2次,两次提取液合并,用管式离心机离心除杂,将除杂后的提取液于65℃的条件下减压浓缩至60℃时相对密度为1.20的膏体,将浓缩后的膏体用喷雾干燥器干燥成粉末; 第三步,将剩余原料药材按所述比例混合,加相对于获得的混合物质量的3倍的水溶解,加热煎煮2小时,过滤;将滤渣再次用相对于获得的混合物质量的2倍的水浸泡,加热煎煮1小时,过滤;合并两次过滤液,减压浓缩除去水分,干燥并粉碎成粉末; 第四步,将第一步、第二步和第三步获得的粉末混合,进一步加入相对于获得的混合物质量0.05倍的羧甲基淀粉钠、0.05倍的微晶纤维素,混匀,制粒,干燥后,加入相对于获得的混合物质量0.02倍的硬脂酸镁,然后用冲压装置将颗粒压制成片,即得含片剂。
实施例2 本发明的喷雾剂
取当归20g、牡蛎肉11g、肉苁蓉26g、菟丝子13g、紫菀17g、血叶兰27g、褐云玛瑙螺11g、白芍19g、何首乌15g、楮实子18g、北沙参15g、麦冬26g、桑椹23g、龟甲13g、地柏枝20g、竹沥24g、知母16g、荸荠23g、栝楼11g、紫苏叶21g、川楝子7g、蔓荆子15g、大青叶29g、薄荷18g、牛蒡子23g、葛根15g、地骨皮19g、白薇15g、龙眼肉19g、山毛藓25g、刺五加13g、远志17g和柏子仁15g。
其制备方法包括以下步骤:
a、按所述比例称取所有原料药材,加相对于获得的混合物质量4倍的水浸泡6小时,武火煮沸后,改用文火慢煎30分钟至药液的剂量为150ml,煎煮3次,合并煎煮液过滤,滤液加热得浸膏1,药渣备用;
b、将步骤a的药渣加90%乙醇浸泡1小时,提取两次,每次1小时,合并提取液,120目滤过,取6000转/分钟离心后的上清液,经截流分子量为8000的超滤柱超滤,超滤液减压浓缩得相对密度为80℃时1.35的浸膏2;
c、将浸膏1和浸膏2混合,加水稀释即得喷雾剂。
实施例3 本发明的滴剂
取当归16g、牡蛎肉16g、肉苁蓉22g、菟丝子10g、紫菀21g、血叶兰24g、褐云玛瑙螺19g、白芍18g、何首乌18g、楮实子14g、北沙参8g、麦冬20g、桑椹24g、龟甲9g、地柏枝18g、竹沥27g、知母22g、荸荠26g、栝楼10g、紫苏叶23g、川楝子8g、蔓荆子21g、大青叶23g、薄荷16g、牛蒡子19g、葛根23g、地骨皮25g、白薇13g、龙眼肉25g、山毛藓17g、刺五加11g、远志23g和柏子仁10g。
其制备方法包括以下步骤:
a、取所述原料药加入水提取2次,第一次加4倍量水煎煮2小时,第二次加3倍量水煎煮1小时,将2次提取液合并,滤过,减压浓缩得80℃时相对密度为1.10的浸膏1,药渣备用;
b、将药渣加90%乙醇浸泡1小时,提取两次,每次1小时,合并提取液,滤过,浓缩,120目滤过,8000转/分钟离心,取上清液,经截流分子量为8000的超滤柱超滤,超滤液减压浓缩相对密度为60℃时1.25的浸膏2;
c、将浸膏1和浸膏2混合,加入混合浸膏总质量的0.06%的氯化钠和60倍的蒸馏水,并加入浓度为4%氢氧化钠溶液调节PH为6.5,再加入0.2%活性炭煮沸10分钟,滤过,分装,灭菌,即得滴剂。
毒性试验:
急性毒性试验:应用NIH小鼠40只,SPF级,雌雄各半,体重17~24g,进行急性毒性试验。小鼠随机分为两组,每组20只,即对照组和给药组,实验前禁食12小时;将本发明的实施例1制备的含片剂溶解在水中,(浓度为5.74g生药/ml,最高浓度)灌胃,灌胃容积为5ml/kg(即单次给药剂量为28.7生药/kg),对照组给予等量生理盐水,一天给药2次,给药间隔时间6小时,给药后连续观察14天,并记录小鼠的毒性反应及死亡数。实验结果表明:与对照组比较,给药后小鼠未见明显差异,实验连续观察14天,小鼠全身状况、饮食、饮水、体重增长均正常。小鼠口服灌胃本发明的含片剂LD50>28.7生药/kg,每日最大给药量为57.4生药/kg/日。本发明的药物临床用药量为4.6g生药/日/人,成人体重以60kg计,平均用药剂量为0.077g生药/kg/日。按体重计:小鼠(平均体重以21g计)口服灌胃本发明的药物的耐受量为临床用量的745倍。因此本发明实施例1的含片剂急性毒性低,临床用药安全。
长期毒性实验:将本发明实施例2的喷雾剂对小鼠按6.43、15.72和36.41g生药/kg连续用药16周(1.0ml/100g体重,每天2次)及停药4周后,结果表明:本发明中药制剂对小鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药16周及停药4周后,小鼠各脏器均无明显改变。说明本发明药物制剂对小鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
长期毒性实验:将本发明实施例3的滴剂对小鼠按6.43、15.72和36.41g生药/kg连续用药16周(1.0ml/100g体重,每天2次)及停药4周后,结果表明:本发明药物制剂对小鼠的毛发、行为、大小便、体重、脏器重量、血象、肝肾功能、血糖、血脂等指标均无明显影响,脏器肉眼没有发现异样变化和组织学检查结果表明,用药16周及停药4周后,小鼠各脏器均无明显改变。说明本发明药物制剂对小鼠长期用药后毒性小,停药后也没有异样反应,应用安全。
病例选择: 选取复发性口腔溃疡女性患者220 例,年龄18-48岁,平均(33.1±1.7)岁,病程平均(3.7±1.3)年;全部患者随机分为四组,四组患者在年龄、病程及病情严重程度等一般资料方面组间差异无统计学意义(P>0.05),具有可比性。
含片剂治疗组:55人。
喷雾剂治疗组:55人。
滴剂治疗组:55人。
对照组:55人。
诊断标准:
参照《中医病证诊断疗效标准》:
1、以口腔粘膜出现单个或数个直径 3 ~ 5mm 的溃疡,灼热疼痛为主要症状 ;
2、起病较快,一般10天左右愈合,若此伏彼起,则病程延长,愈后常易复发 ;
3、口腔检查 :口腔粘膜溃疡较表浅,圆形或椭圆形,数量少则1~2个,多则10余个,表面有淡黄色分泌物附着,溃疡周围粘膜大多充血。
且根据中医望、闻、问、切辨证进一步诊断为血虚阴亏型复发性口腔溃疡。
治疗方法:
含片剂治疗组:口含本发明实施例1制备的含片剂,4次/d,一次1片,疗程为5天。
喷雾剂治疗组:用本发明实施例2制备的喷雾剂喷溃疡部位,4次/d,疗程为5天。
滴剂治疗组:用本发明实施例3制备的滴剂滴于溃疡处,4次/d,疗程为5天。
对照组:用三金桂林西瓜霜喷剂喷涂溃疡部位,4次/d,疗程为5天。
疗效标准:
根据国家中医药管理局领布的《中医病证诊断疗效标准ZY/T001.1-94》口疮的疗效评定。
治愈: 口腔溃疡愈合,局部无不适感,随访半年未再复发。
好转: 口疮虽然时有复发,但数量减少,程度减轻。
未愈: 口疮症状及溃疡无明显变化。
治疗结果:
参见表1,从表1可以看出,采用本发明的药物治疗血虚阴亏型复发性口腔溃疡,相对于传统药物在治疗效果上,具有显著的改进。
表1 四组分别治疗5天后临床疗效比较 例
| 组别 | 例数 | 治愈 | 好转 | 未愈 | 总有效率 |
| 含片剂治疗组 | 55 | 32 | 22 | 1 | 98.2% |
| 喷雾剂治疗组 | 55 | 34 | 21 | 0 | 100.0% |
| 滴剂治疗组 | 55 | 36 | 19 | 0 | 100.0% |
| 对照组 | 55 | 21 | 24 | 10 | 81.8% |
根据上述表格内的临床统计可知,含片剂治疗组总有效率98.2%,喷雾剂治疗组总有效率100.0%,滴剂治疗组总有效率100.0%,对照组总有效率81.8%,本发明提供的药物具有有效率高、疗效确切、安全性高、无毒副作用的优势。
同时对治愈和好转的患者随访1年,结果统计:
含片剂治疗组治愈和好转54例,复发5例,复发率9.25%;
喷雾剂治疗组治愈和好转55例,复发6例,复发率10.9%;
滴剂治疗组治愈和好转55例,复发4例,复发率7.3%;
对照组治愈和好转45例,复发15例,复发率33.3%。
从以上临床统计可知,本发明提供的药物治疗后复发率比传统药物显著降低。
典型病例:董某,女,32岁,2012年10月就诊,患者近2天下唇及两颊部多发溃疡,疼痛难忍,经患者自述得知其患口腔溃疡反复发作2年多,以前曾用过多种西药疗效不佳。经查: 口腔内有4-6处溃疡,溃疡面积大小不等,周围红赤,中央凹陷,五心烦热,口干喜饮,舌淡苔薄白,脉细数无力,确诊为血虚阴亏型复发性口腔溃疡。服用本发明实施例2的喷雾剂进行治疗,每日四次,连续5天后,口腔溃疡愈合,症状消失痊愈。随访1年再未复发。
以上所述仅为本发明的较佳实施例,并不用以限制本发明,凡在本发明的精神和原则之内,所作的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (9)
1.一种治疗血虚阴亏型复发性口腔溃疡的药物,其特征在于,包括以下原料药材:当归、牡蛎肉、肉苁蓉、菟丝子、紫菀、血叶兰、褐云玛瑙螺、白芍、何首乌、楮实子、北沙参、麦冬、桑椹、龟甲、地柏枝、竹沥、知母、荸荠、栝楼、紫苏叶、川楝子、蔓荆子、大青叶、薄荷、牛蒡子、葛根、地骨皮、白薇、龙眼肉、山毛藓、刺五加、远志和柏子仁。
2.根据权利要求1所述的药物,其特征在于,所述药物中各原料药材的重量份数比为:当归12-23份、牡蛎肉10-18份、肉苁蓉20-30份、菟丝子8-16份、紫菀15-23份、血叶兰22-28份、褐云玛瑙螺10-21份、白芍15-26份、何首乌10-20份、楮实子12-23份、北沙参6-16份、麦冬13-27份、桑椹22-29份、龟甲8-15份、地柏枝16-25份、竹沥22-28份、知母10-23份、荸荠22-28份、栝楼8-14份、紫苏叶20-26份、川楝子5-9份、蔓荆子11-22份、大青叶22-32份、薄荷15-23份、牛蒡子17-24份、葛根10-24份、地骨皮16-28份、白薇11-25份、龙眼肉18-26份、山毛藓14-27份、刺五加10-19份、远志16-24份和柏子仁8-16份。
3.根据权利要求1或2所述的药物,其特征在于,所述药物中各原料药材的重量份数比为:当归14-20份、牡蛎肉11-16份、肉苁蓉22-29份、菟丝子10-15份、紫菀17-21份、血叶兰23-27份、褐云玛瑙螺11-19份、白芍18-22份、何首乌13-18份、楮实子14-21份、北沙参8-15份、麦冬15-26份、桑椹23-27份、龟甲9-13份、地柏枝18-24份、竹沥24-27份、知母11-22份、荸荠23-26份、栝楼10-13份、紫苏叶21-25份、川楝子6-8份、蔓荆子12-21份、大青叶23-29份、薄荷16-21份、牛蒡子18-23份、葛根12-23份、地骨皮17-25份、白薇13-22份、龙眼肉19-25份、山毛藓15-25份、刺五加11-18份、远志17-23份和柏子仁10-15份。
4.根据权利要求1-3任一所述的药物,其特征在于,所述药物中各原料药材的重量份数比为:当归14份、牡蛎肉15份、肉苁蓉29份、菟丝子15份、紫菀20份、血叶兰23份、褐云玛瑙螺16份、白芍22份、何首乌13份、楮实子21份、北沙参13份、麦冬15份、桑椹27份、龟甲11份、地柏枝24份、竹沥25份、知母11份、荸荠24份、栝楼13份、紫苏叶25份、川楝子6份、蔓荆子12份、大青叶25份、薄荷21份、牛蒡子18份、葛根23份、地骨皮17份、白薇22份、龙眼肉23份、山毛藓15份、刺五加18份、远志19份和柏子仁13份。
5.根据权利要求1-3任一所述的药物,其特征在于,所述药物中各原料药材的重量份数比为:当归20份、牡蛎肉11份、肉苁蓉26份、菟丝子13份、紫菀17份、血叶兰27份、褐云玛瑙螺11份、白芍19份、何首乌15份、楮实子18份、北沙参15份、麦冬26份、桑椹23份、龟甲13份、地柏枝20份、竹沥24份、知母16份、荸荠23份、栝楼11份、紫苏叶21份、川楝子7份、蔓荆子15份、大青叶29份、薄荷18份、牛蒡子23份、葛根15份、地骨皮19份、白薇15份、龙眼肉19份、山毛藓25份、刺五加13份、远志17份和柏子仁15份。
6.根据权利要求1-3任一所述的药物,其特征在于,所述药物中各原料药材的重量份数比为:当归16份、牡蛎肉16份、肉苁蓉22份、菟丝子10份、紫菀21份、血叶兰24份、褐云玛瑙螺19份、白芍18份、何首乌18份、楮实子14份、北沙参8份、麦冬20份、桑椹24份、龟甲9份、地柏枝18份、竹沥27份、知母22份、荸荠26份、栝楼10份、紫苏叶23份、川楝子8份、蔓荆子21份、大青叶23份、薄荷16份、牛蒡子19份、葛根23份、地骨皮25份、白薇13份、龙眼肉25份、山毛藓17份、刺五加11份、远志23份和柏子仁10份。
7.根据权利要求1-6任一所述的药物,其特征在于,所述药物的剂型为含片剂时,其制备方法包括以下步骤:
第一步,将当归、菟丝子、褐云玛瑙螺、楮实子、地柏枝、竹沥、知母、葛根、地骨皮、刺五加和柏子仁按所述比例混合,用相对于获得的混合物质量的4~6倍的醇浓度90%~95%的乙醇浸泡,加热回流2~4小时后提取,过滤;将滤渣再次用相对于获得的混合物质量的2~4倍的醇浓度85%~95%的乙醇浸泡,加热回流1~2小时后提取,过滤;合并两次过滤液,减压回收乙醇并浓缩至药液浓度为0.8~1.2g生药/mL,利用体积为5L的大孔吸附树脂柱洗脱两次,先用5倍树脂柱体积的去离子水或蒸馏水洗脱,再用3倍树脂柱体积的醇浓度为90%~95%乙醇洗脱,收集乙醇洗脱液,减压浓缩除去乙醇,干燥并粉碎成粉末; 第二步,将牡蛎肉、白芍、何首乌、龟甲、荸荠、栝楼、白薇、龙眼肉、山毛藓和远志按所述比例混合,加相对于获得的混合物质量的3~5倍的醇浓度85%~95%的乙醇加热回流提取2次,两次提取液合并,用管式离心机离心除杂,将除杂后的提取液于60℃~70℃的条件下减压浓缩至60℃时相对密度为1.20~1.23的膏体,将浓缩后的膏体用喷雾干燥器干燥成粉末; 第三步,将剩余原料药材按所述比例混合,加相对于获得的混合物质量的2~5倍的水溶解,加热煎煮2~4小时,过滤;将滤渣再次用相对于获得的混合物质量的1~3倍的水浸泡,加热煎煮1~2小时,过滤;合并两次过滤液,减压浓缩除去水分,干燥并粉碎成粉末; 第四步,将第一步、第二步和第三步获得的粉末混合,进一步加入相对于获得的混合物质量0.05~0.1倍的羧甲基淀粉钠、0.05~0.1倍的微晶纤维素,混匀,制粒,干燥后,加入相对于获得的混合物质量0.01~0.05倍的硬脂酸镁,然后用冲压装置将颗粒压制成片,即得含片剂。
8.根据权利要求1-6任一所述的药物,其特征在于,所述药物的剂型为喷雾剂时,其制备方法包括以下步骤:
a、按所述比例称取所有原料药材,加相对于获得的混合物质量3-5倍的水浸泡3-10小时,武火煮沸后,改用文火慢煎30-50分钟至药液的剂量为100-300ml,煎煮3次,合并煎煮液过滤,滤液加热得浸膏1,药渣备用;
b、将步骤a的药渣加60-90%乙醇浸泡0.5-1.5小时,提取两次,每次1-2小时,合并提取液,80-160目滤过,取6000-10000转/分钟离心后的上清液,经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩得相对密度为80℃时1.35的浸膏2;
c、将浸膏1和浸膏2混合,加水稀释即得喷雾剂。
9.根据权利要求1-6任一所述的药物,其特征在于,所述药物的剂型为滴剂时,其制备方法包括以下步骤:
a、取所述原料药加入水提取2次,第一次加4-6倍量水煎煮1-2小时,第二次加3-5倍量水煎煮1-2小时,将2次提取液合并,滤过,减压浓缩得80℃时相对密度为1.04~1.10的浸膏1,药渣备用;
b、将药渣加60-90%乙醇浸泡0.5-1.5小时,提取两次,每次1-2小时,合并提取液,滤过,浓缩,80-160目滤过,6000-10000转/分钟离心,取上清液,经截流分子量为5000-10000的超滤柱超滤,超滤液减压浓缩相对密度为60℃时1.25的浸膏2;
c、将浸膏1和浸膏2混合,加入混合浸膏总质量的0.06%的氯化钠和60-80倍的蒸馏水,并加入浓度为4%氢氧化钠溶液调节PH为6.0-7.0,再加入0.2%
活性炭煮沸10分钟,滤过,分装,灭菌,即得滴剂。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510167973.9A CN104740403A (zh) | 2015-04-10 | 2015-04-10 | 一种治疗血虚阴亏型复发性口腔溃疡的药物及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510167973.9A CN104740403A (zh) | 2015-04-10 | 2015-04-10 | 一种治疗血虚阴亏型复发性口腔溃疡的药物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104740403A true CN104740403A (zh) | 2015-07-01 |
Family
ID=53581023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510167973.9A Withdrawn CN104740403A (zh) | 2015-04-10 | 2015-04-10 | 一种治疗血虚阴亏型复发性口腔溃疡的药物及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104740403A (zh) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031577A (zh) * | 2015-07-10 | 2015-11-11 | 冉宇欣 | 一种治疗血虚阴亏型口腔溃疡的药物及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784933A (zh) * | 2014-03-07 | 2014-05-14 | 王爱文 | 复发性口腔溃疡散 |
-
2015
- 2015-04-10 CN CN201510167973.9A patent/CN104740403A/zh not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103784933A (zh) * | 2014-03-07 | 2014-05-14 | 王爱文 | 复发性口腔溃疡散 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031577A (zh) * | 2015-07-10 | 2015-11-11 | 冉宇欣 | 一种治疗血虚阴亏型口腔溃疡的药物及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520578B (zh) | 一种治疗口腔溃疡的中药组合物及其制备方法 | |
| CN103520572B (zh) | 一种用于治疗特应性皮炎的中药组合物及其制备方法 | |
| CN104398986A (zh) | 一种安神补脑的淫羊藿口服液及其制备方法 | |
| CN103751633A (zh) | 一种治疗下肢静脉曲张的中药组合物及其制备方法 | |
| CN102000164B (zh) | 一种治疗银屑病的中药组合物及其制备方法 | |
| CN103638250B (zh) | 一种治疗面神经麻痹的中药制剂及其制备方法 | |
| CN102366541B (zh) | 一种治疗消渴病的中药组合物 | |
| CN105213941A (zh) | 一种用于治疗小儿腹泻的中药组合物及其制备方法 | |
| CN104127813A (zh) | 一种治疗气血两虚型褥疮的中药组合物及其制备方法 | |
| CN104069474A (zh) | 一种治疗脂溢性脱发的中药组合物及其制备方法 | |
| CN103007145B (zh) | 一种治疗小儿轮状病毒肠炎的中药组合物及其制备方法 | |
| CN103520643B (zh) | 一种用于治疗糖尿病白内障的中药制剂及其制备方法 | |
| CN103705639B (zh) | 一种治疗脑积水的中药制剂 | |
| CN104740403A (zh) | 一种治疗血虚阴亏型复发性口腔溃疡的药物及其制备方法 | |
| CN104667183A (zh) | 治疗湿热邪滞型化脓性骨髓炎的药物制剂及其制备方法 | |
| CN104800610A (zh) | 一种治疗帕金森病的中药制剂及其制备方法 | |
| CN104258224A (zh) | 一种治疗肺肾阴虚型慢性支气管炎的五味子口服液及其制备方法 | |
| CN107137689A (zh) | 一种治疗更年期综合征的中药组合物 | |
| CN105456933A (zh) | 一种活血化瘀、通经活络的中药及其制备方法 | |
| CN105998979A (zh) | 一种治疗肺肾阴虚型慢性咽炎的中药组合物及方法 | |
| CN105031135A (zh) | 一种治疗肝肾虚损型痛经的中药组合物及其制备方法 | |
| CN104922595A (zh) | 一种用于带状疱疹的中药制剂及其制备方法 | |
| CN103083552B (zh) | 一种用于治疗神经性皮肤炎症的药丸 | |
| CN103860979B (zh) | 一种治疗肛隐窝炎的中药制剂及其制备方法 | |
| CN105267895A (zh) | 用于治疗牛产后血瘀型胞衣不下的药物及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20150701 |
|
| WW01 | Invention patent application withdrawn after publication |